Fidelity Small-Mid Multifactor ETF
FSMD - ETF AI Analysis
Top Page
Fidelity Small-Mid Multifactor ETF (FSMD)
FSMD, the Fidelity Small-Mid Multifactor ETF, earns a solid overall rating largely because several key holdings like Incyte, Exelixis, Loews, and East West Bancorp show strong financial performance, reasonable valuations, and generally positive momentum, which support the fund’s quality. However, weaker names such as Guardant Health and Hasbro, where financial instability, high debt, and valuation concerns are more prominent, slightly weigh on the rating, and investors should note the risk that some holdings face profitability and cash flow challenges.
FSMD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.47B
- Region
- North America
- Expense Ratio
- 0.15%
- Beta
- 0.83
- Issuer
- Fidelity
- Inception Date
- Feb 26, 2019
- Dividend Yield
- 1.30%
- Asset Class
- Equity
- Index Tracked
- Fidelity Small-Mid Multifactor Index
FSMD Summary
FSMD is the Fidelity Small-Mid Multifactor ETF, which follows the Fidelity Small-Mid Multifactor Index and focuses on smaller and mid-sized U.S. companies. It spreads investments across many sectors, including financials, technology, health care, and industrials. Some well-known names in the fund include Tenet Healthcare and Dynatrace. Investors might consider FSMD for diversification beyond large, well-known companies and for the potential growth that smaller firms can offer. However, because it invests in small and mid-sized stocks, its price can be more volatile and can go up and down sharply with changes in the market.
How much will it cost me?
FSMD has an expense ratio of 0.15%, which means you’ll pay about $1.50 per year for every $1,000 invested. This cost is lower than the average ETF because it uses a mostly rules-based, multifactor strategy rather than being fully actively managed by stock-picking managers.
What would affect this ETF?
FSMD focuses on U.S. small and mid-sized companies across sectors like financials, technology, industrials, and health care, so it could benefit if the U.S. economy grows steadily, business investment rises, and innovation in areas like software and medical technology continues. On the downside, higher interest rates, an economic slowdown that hits smaller companies harder, or sector-specific issues in financials, health care, or energy could weigh on the ETF’s performance, especially given its exposure to names like Tenet Healthcare, Dynatrace, and HF Sinclair.
FSMD Top 10 Holdings
FSMD leans into U.S. small and mid-cap names with a noticeable tilt toward tech, health care, and energy, and that mix is shaping returns. Energy players like Permian Resources and APA have been rising, giving the fund a strong tailwind, while HF Sinclair adds steady support despite some margin worries. On the growth side, software names such as Dynatrace and Nutanix are contributing, but their momentum looks a bit mixed, hinting at some volatility under the hood. nVent Electric, meanwhile, has been lagging lately, slightly dragging on an otherwise broadly diversified, U.S.-focused lineup.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Everpure | 0.58% | $14.40M | $36.69B | 28.62% | 64Neutral | |
| Tenet Healthcare | 0.45% | $11.30M | $22.83B | 45.44% | 74Outperform | |
| Incyte | 0.38% | $9.36M | $24.81B | 14.76% | 81Outperform | |
| Guardant Health | 0.37% | $9.28M | $20.95B | 61.16% | 61Neutral | |
| Reinsurance Group | 0.37% | $9.21M | $17.81B | 44.47% | 74Outperform | |
| Hasbro | 0.36% | $9.08M | $16.99B | 52.79% | 56Neutral | |
| Revvity | 0.36% | $9.06M | $17.53B | 65.30% | 67Neutral | |
| Exelixis | 0.36% | $9.04M | $17.04B | 62.93% | 78Outperform | |
| Loews | 0.36% | $8.99M | $22.61B | 7.19% | 76Outperform | |
| East West Bancorp | 0.35% | $8.82M | $17.97B | 26.47% | 79Outperform |
FSMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FSMD, the sentiment is Positive. The current price of 50.15 is above the 20-day moving average (MA) of 50.11, above the 50-day MA of 50.03, and above the 200-day MA of 49.09, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 67.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSMD.
FSMD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $50.15 | $54.00(7.68% Upside) | $2.47B | 0.15% | 70Neutral | |
| $31.63 | $39.42(24.63% Upside) | $3.67B | 0.51% | 66Neutral | |
| $42.03 | $51.70(23.00% Upside) | $3.28B | 0.55% | 68Neutral | |
| $74.67 | $90.31(20.95% Upside) | $2.94B | 0.24% | 66Neutral | |
| $52.71 | $68.30(29.58% Upside) | $2.64B | 0.36% | 66Neutral | |
| $106.18 | $125.54(18.24% Upside) | $1.85B | 0.29% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FSMD | Fidelity Small-Mid Multifactor ETF | 50.15 | 8.41 | 20.16% | |
| CGMM | Capital Group U.S. Small and Mid Cap ETF | 31.63 | 4.63 | 17.14% | |
| TMSL | T. Rowe Price Small-Mid Cap ETF | 42.03 | 8.23 | 24.34% | |
| JMEE | JPMorgan Market Expansion Enhanced Equity ETF | 74.67 | 13.76 | 22.58% | |
| PRFZ | Invesco FTSE RAFI US 1500 Small-Mid ETF | 52.71 | 9.60 | 22.26% | |
| USVM | VictoryShares USAA MSCI USA Small Cap Value Momentum ETF | 106.18 | 20.37 | 23.74% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
